Aina Liu

Real-World Efficacy of Cadonilimab Plus Chemotherapy as Second-Line Therapy in Immunotherapy-Pretreated Advanced HER2 Negative Gastric or Gastroesophageal Junction Cancer

Zeyu Liu, Yanwu Lü, Ming Li, Jinyu Xiang et autres

Background: Immunotherapy is now a cornerstone of first-line treatment for advanced gastric or gastroesophageal junction cancer (G/GEJC). However, optimal second-line options after progression on first-line immunotherapy are undefined. Given the established efficacy of cadonilimab in the first-line setting, this real-world study evaluated …

cn (code pays fourni par la source)

PDPN+ cancer-associated fibroblasts correlate with the neoadjuvant immunotherapy response in gastric cancer

Mi Jian, Zhensong Yang, Yutao Tang, Fangjie Jiang et autres

The achievement of pathological complete response (pCR) with neoadjuvant therapy can significantly improve prognosis in patients with gastric cancer (GC). GC tissues demonstrating pCR after immunotherapy exhibited increased stiffness and proliferation of fibroblasts within the stroma. Specific subpopulation cancer-associated fibroblasts (CAFs) may …

cn (code pays fourni par la source)

SHMT proteins: An emerging set of serine hydroxymethyltransferase in cancer

Rong Fu, Fulin Sun, Wenbo Wang, Ruixuan Wang et autres

cn (code pays fourni par la source)

Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from the RCTS trial.

Lian Liu, Li Song, Zimin Liu, Yanguo Liu et autres

4059 Background: Anti-PD1 antibody has significantly improved survival in patients with HER2-overexpressing and PD-L1 combined positive score (CPS) ≥1 GC/GEJC when added to trastuzumab and chemotherapy. Recent trials revealed that HER2-targeted antibody-drug conjugates, including RC48 and Trastuzumab Deruxtecan, combined with anti-PD1 antibody, …

cn (code pays fourni par la source)

Efficacy and safety of sintilimab combined with trastuzumab and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction cancer

Zeyu Liu, Aina Liu, Ming Li, Jinyu Xiang et autres

Background: To evaluate the efficacy and safety of sintilimab in combination with trastuzumab and chemotherapy for HER2-positive advanced gastric/gastroesophageal junction cancer (GC/GEJC). Methods: HER2-positive advanced GC/GEJC patients admitted to our department between January 2018 and October 2024 were included in this study. …

cn (code pays fourni par la source)

Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS).

Li Song, Zimin Liu, Yanguo Liu, Kainan Li et autres

4009 Background: Integrating immunotherapy with trastuzumab and chemotherapy has shown a significant improvement in overall response rate (ORR) and progression-free survival (PFS) in HER2-overexpression gastric or gastroesophageal junction cancer (GC/GEJC). However, the overall survival (OS) did not achievestatistical significance, and there was …

cn (code pays fourni par la source)

Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study

Jinyu Xiang, Wenjing Gong, Ping Sun, Xuan Wang et autres

Background: Nivolumab combined with chemotherapy has been shown to improve prognosis in patients with untreated, human epidermal growth factor receptor 2 (HER2)-negative advanced gastric cancer (GC) and programmed death ligand-1 (PD-L1) combined positive score (CPS) ≥5. However, the available first-line treatment options …

cn (code pays fourni par la source)

Complete remission of alpha-fetoprotein-producing gastric cancer by combined tislelizumab-apatinib treatment of a patient with proficient mismatch repair: a case report

Jinyu Xiang, Wenjing Gong, Congcong Wang, Ping Sun et autres

BACKGROUND: Alpha‑fetoprotein-producing gastric cancer (AFPGC) is a rare type of gastric cancer with a high rate of metastasis and poor prognosis. Despite substantial progress in the treatment of many solid tumors, there are no reports of the safety and effectiveness of immune …

cn (code pays fourni par la source)

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience

Fengze Sun, Dawei Wang, Aina Liu, Tianqi Wang et autres

Background: Programmed death 1 (PD-1) inhibitors—tislelizumab, toripalimab, camrelizumab, and sintilimab—are used for advanced urothelial carcinoma (UC) in China. To date, the efficacy and adverse events (AEs) of these PD-1 inhibitors have been poorly reported for advanced UC. Methods: We reviewed 118 patients …

cn (code pays fourni par la source)

The combination of Tislelizumab and apatinib obtained complete remission for alpha-fetoprotein-producing gastric cancer with microsatellite stability: case report

Jinyu Xiang, Congcong Wang, Wenjing Gong, Aina Liu et autres

cn (code pays fourni par la source)

An N6-Methyladenosine-Related Gene Set Variation Score as a Prognostic Tool for Lung Adenocarcinoma

Huijuan Zhang, Jing Hu, Aina Liu, Huajun Qu et autres

N6-methyladenosine (m6A) is the most prevalent type of RNA modification, and we hypothesized that patterns of m6A-related genes may be useful for estimating risk of lung adenocarcinoma (LUAD). An m6A-related gene set variation score (m6A-GSVS) was generated using RNA-sequencing data from LUAD …

cn (code pays fourni par la source)

Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study

Fenge Jiang, Huijuan Zhang, Caiyan Yu, Aina Liu

This study was to investigate the efficacy and safety of regorafenib or fruquintinib combined with camrelizumab in patients with microsatellite stable (MSS) and/or proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC). Medical records of MSS/pMMR mCRC patients who received regorafenib (80 mg) …

cn (code pays fourni par la source)